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reprioritizes test order to screen-confirm-mix, recommending that the mixing test is initiated only when screen and confirm analysis is not clear-cut and/or when other causes of prolonged clotting times are known or suspected. 5 The present study retrospectively assesses diagnostic data from 311 plasma samples from non-anticoagulated patients deemed LA-positive according to the BSH guideline, and by extension the CLSI guideline, by subsequently applying interpretations based on integrated testing, and the classical algorithm.
| MATERIALS AND METHODS

| Blood collection, manipulation, and storage
Blood was collected into Vacuette tubes (Greiner Bio-One Ltd, Stonehouse, UK) containing a one-tenth volume of 0.105 mol L −1 (3.2%) tri-sodium citrate and double centrifuged to obtain platelet poor plasma (PPP) [3] [4] [5] which was stored at −80°C until use.
| Lupus anticoagulant assays
Routine dRVVT was performed with Life Diagnostics (LD) and confirm clotting times were converted to normalized ratios via their reference interval (RI) mean clotting times. 5, 10, 16, 17 Results were defined as consistent with the presence of a LA if the screen ratio was greater than the RI upper limit with ≥10% correction by the confirm ratio [2] [3] [4] [5] 15, 16, [18] [19] [20] , which had been previously locally validated.
dRVVT and dAPTT to increase specificity [4] [5] [6] 12, 13 , particularly where confirm ratios were themselves elevated. 5, 6, 12, 13 In view of potential differences between normal pooled plasma (NPP) and RI mean clotting times, 5, 16 mixing test ratios were derived from NPP results as denominator so that the ratios reflected the effect of index plasmas on the NPP in which they were mixed. 20 Mixing test ratio specific cut-off was employed to determine presence of inhibition. 3, 5, 20, 21 The
RIs, and thus cut-offs, had previously been locally derived from 43 normal donor plasmas. [3] [4] [5] 22 
| Patients
Diagnostic data from routine LA testing at Guy's and St. Thomas' Hospitals for 311 non-anticoagulated patients interpreted as LApositive by following the BSH/CLSI algorithms were re-evaluated by applying integrated testing alone to screen and confirm results from undiluted plasma, and also the classical algorithm where an elevated screen but negative mixing test precludes performance of a confirm test and allows classification of the sample as being LA-negative. The ratio generated from integrated testing was derived from screen ratio/confirm ratio and not from raw clotting times because clotting times for the paired screen and confirm reagents with NPP differed for both dRVVT and dAPTT. 2, 18 Schematics of the algorithms are shown in Figure 1 .
One hundred and six of the patients had antiphospholipid syndrome (APS), 35 had systemic lupus erythematosus (SLE) and persistent LA, 26 had SLE and first LA-positive testing, and 144 were clinically appropriate patients being investigated for APS. Seventy of the 106 (66%) APS patients also had elevated aCL and/or aβ2GPI.
| RESULTS AND DISCUSSION
The lack of gold standard assays and reference plasmas continues to hamper standardisation of LA detection. Instead, diagnostic The mild elevations were considered to be due to the LA and not un- of dRVVT interpretations to LA-negative ( Table 2 ). Four of those were dAPTT-positive, one of which also had elevated aCL and aβ 2 GPI, two had elevated mixing tests, one of which had had elevated aCL and aβ 2 GPI, and the other 2 had established, persistent LA. Their dRVVT screen ratios ranged from 1.18-1.29, mean 1.23, median 1.23. Thus, they were all likely false-negatives arising from differences in sensitivity between the percent correction and integrated ratio cut-offs.
The 10% correction value has been advocated by BSH guidelines since 1991 4,18,29 and had been locally validated for dRVVT and dAPTT from reference range data. 3 All dAPTT interpretations remained LA-positive with integrated testing.
One omission from our study is integrated testing on samples deemed LA-negative from BSH/CLSI or classical algorithms because dRVVT and dAPTT screen ratios were within reference ranges. Whilst it can be reasonably argued that normal screen ratios do not fulfill one of the crucial diagnostic criteria, being elevation of a phospholipiddependent screening test, a converse view exists suggesting that screen and confirm discordance will detect weaker LA that prolong screen clotting times above a patient-specific baseline but not beyond the cut-off of from a population distribution. Cut-offs for dRVVT screen ratio, percent correction, integrated ratio and mixing test ratio respectively were 1.17, 10.0, 1.13, 1.13, and for dAPTT, 1.20, 10.0, 1.10, 1.15. Of the 52 dRVVT mixing test negative samples, 20 were from patients with APS, seven were from patients with SLE (three of which had persistent LA), and the majority of the remainder were being tested in response to thrombosis or recurrent miscarriage; 22 of 52 (42.3%) had elevated aCL and/or aβ2GPI. Of the 111 dAPTT mixing test negative samples, 25 were from patients with APS, 26 were from patients with SLE (six of which had persistent LA), four were in response to an elevated routine APTT, and the majority of the remainder were being tested in response to thrombosis or recurrent miscarriage More specific assays have been reported to be less affected 9 , which is mirrored in the data for this study where dRVVT was less affected by false-negative mixing tests than dAPTT. Comparative data between LA-positive and LA-negative samples via this algorithm are given in (those with lower screen ratios) and prompt confirmatory test performance in the classical algorithm. However, there was some degree of cross-over with some samples whose screen ratios in undiluted plasma were close to cut-offs nonetheless elevating mixing tests, whilst some others with moderately elevated screen ratios (dRVVT up to 1.44, dAPTT up to 1.68) did not. Manifestation in mixing tests seems to be a function of more than just potency, other possible contributory factors include epitope specificity, antibody avidity, and reagent composition. 20 In summary, the number of samples classified as LA-positive differed depending on the method of interpretation, particularly in the case of the classical algorithm where a design limitation of mixing tests precluded completion of the assay medley that could otherwise reveal an LA. The discrepancies occurred mainly with samples whose screen ratios were slightly, and occasionally moderately, elevated, a common area of between-center discordance in external quality assurance challenges. 8 The absence of reference plasmas and gold standard assays means that we cannot be certain which of these arguably ambiguous result sets reflect genuine LA and those with positive mixing tests can engender increased confidence in specificity. A major contributor to between-department discrepancies with lower titer antibodies irrespective of the algorithm employed is cut-off generation. It is widely accepted, and recommended in all guidelines, that cut-offs must be
locally derived yet laboratories vary in their approach to this issue and some laboratories continue to adopt manufacturers' generic cut-offs.
Conversely, no assay is perfect and the dilution effect is a genuine confounder, so performing mix and confirm tests in response to an elevated screen coupled with informed interpretation based on clinical data, routine coagulation screening tests and LA-assay design offers us a potentially valuable interpretive middle ground. 
